Italept (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which regulates neurotransmitter release at neuronal synapses. This binding modulates vesicle exocytosis, decreasing excessive glutamate release and lowering neuronal excitability. The resulting stabilization of synaptic transmission helps prevent the hyper‑synchronous firing that triggers seizures.

The appropriate dose of Italept is individualized by the prescribing healthcare professional based on the patient’s age, weight, renal function, seizure type, and response to therapy. Dosage titration typically starts at a low dose and is increased gradually to achieve optimal seizure control while minimizing side effects. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety data for levetiracetam in pregnancy and lactation are limited, and the medication is classified as pregnancy category unknown. Healthcare providers weigh potential benefits against possible risks when prescribing Italept to pregnant or nursing women. Women who are pregnant, planning pregnancy, or breastfeeding should discuss their situation with a physician to determine the most appropriate treatment plan.

To request Italept, visit the product page on gnhindia.com and submit an enquiry specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will ask for trade or institutional credentials. After verification, the sales team provides pricing, availability, shipping details—including any temperature‑controlled handling if needed—and assists with import documentation.

Italept (levetiracetam) offers a distinct mechanism of action by targeting SV2A, which differs from many traditional antiepileptics that modulate ion channels or GABA receptors. It is generally well‑tolerated, has few drug‑enzyme interactions, and does not require routine therapeutic drug monitoring. Compared with older agents such as carbamazepine or phenytoin, levetiracetam may present a lower risk of hepatic enzyme induction and fewer dose‑adjustment challenges.

Italept should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discolored. No special refrigeration is required for this oral formulation.

Italept is taken orally, usually with or without food, as directed by the prescribing clinician. The tablets are swallowed whole with a glass of water. Consistency in timing—taking the dose at the same intervals each day—helps maintain stable drug levels and optimal seizure control. Patients should not crush or chew the tablets unless specifically instructed.

Although uncommon, serious adverse reactions can occur. Patients should be alert for signs of severe skin reactions such as rash, blistering, or peeling, which may indicate Stevens‑Johnson syndrome. New or worsening mood changes, depression, or thoughts of self‑harm require immediate medical attention. Blood abnormalities like neutropenia or thrombocytopenia are also rare but serious; routine blood monitoring may be advised for high‑risk individuals.

Italept is contraindicated in individuals with known hypersensitivity to levetiracetam or any of the tablet’s excipients. Patients with severe renal impairment may require alternative therapy or careful dose adjustment under medical supervision. Additionally, individuals with a history of serious psychiatric disorders should be evaluated closely, as levetiracetam can exacerbate mood disturbances in susceptible patients.